Article ; Online: Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
2022 Volume 26, Issue 6, Page(s) 305.e1–305.e6
Abstract: Purpose: To evaluate refractive and structural outcomes for patients treated for retinopathy of prematurity (ROP) with the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab and "delayed laser," defined as any laser photocoagulation ... ...
Abstract | Purpose: To evaluate refractive and structural outcomes for patients treated for retinopathy of prematurity (ROP) with the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab and "delayed laser," defined as any laser photocoagulation treatment administered at least 2 weeks and <1 year after the initial anti-VEGF injection. Methods: The medical records of infants with type 1 ROP treated between 2015 and 2020 with intravitreal 0.25 mg ranibizumab followed by delayed laser photocoagulation, with a minimum of 6 months' follow-up, were reviewed retrospectively. Refractive and structural outcomes were extracted from the record. Results: A total of 68 eyes of 34 neonates were included, with median gestational age of 24 weeks and birthweight of 657 g. Patients were aged 0.9 to 4.4 years at last follow-up; mean follow-up interval was 2.7 ± 1.02 years. There was no progression to stage 4 or 5 following treatment during the study period. At 2 years' follow-up (mean age, 2.41 ± 0.23 years), median spherical equivalent (SE) was -0.13 D (IQR, 4.20 D). At most recent examination (mean age, 2.70 ± 1.02 years), the most common ocular findings included strabismus (32%), optic atrophy (24%), amblyopia (21%), high myopia (7%), and nystagmus (4%). Conclusions: In our small cohort, neonates with type 1 ROP treated with intravitreal ranibizumab and delayed laser demonstrated good structural outcomes, with no progression to retinal detachment. We found lower rates of high myopia compared with previous reports of laser photocoagulation monotherapy. |
---|---|
MeSH term(s) | Infant ; Infant, Newborn ; Humans ; Child, Preschool ; Ranibizumab/therapeutic use ; Retinopathy of Prematurity/drug therapy ; Retinopathy of Prematurity/surgery ; Bevacizumab/therapeutic use ; Retrospective Studies ; Angiogenesis Inhibitors/therapeutic use ; Intravitreal Injections ; Laser Coagulation ; Vascular Endothelial Growth Factor A ; Gestational Age ; Myopia |
Chemical Substances | Ranibizumab (ZL1R02VT79) ; Bevacizumab (2S9ZZM9Q9V) ; Angiogenesis Inhibitors ; Vascular Endothelial Growth Factor A |
Language | English |
Publishing date | 2022-10-17 |
Publishing country | United States |
Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
ZDB-ID | 1412476-2 |
ISSN | 1528-3933 ; 1091-8531 |
ISSN (online) | 1528-3933 |
ISSN | 1091-8531 |
DOI | 10.1016/j.jaapos.2022.08.524 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5188: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.